Table 1 Registered trials for all diagnoses that are planned, accruing, or closed to accrual and incorporate TTFeilds
From: Tumor treating fields in the management of Glioblastoma: opportunities for advanced imaging
| Â | Title | Phase | Status | NCT Number |
|---|---|---|---|---|
CNS | ||||
 Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM | I | Not yet recruiting | NCT03705351 | |
 NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma | I | Recruiting | NCT03232424 | |
 Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma | I | Recruiting | NCT03223103 | |
 Enhancing Optune Therapy With Targeted Craniectomy | I | Recruiting | NCT02893137 | |
 Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer | I | Active, not recruiting | NCT02903069 | |
 Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma | I | Recruiting | NCT03477110 | |
 TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma | II | Recruiting | NCT02663271 | |
 Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP) | II | Recruiting | NCT03405792 | |
 Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma | II | Active, not recruiting | NCT02743078 | |
 A Phase II Study of NovoTTF-200A Alone and With Temozolomide in Patients With Low-Grade Gliomas | II | Recruiting | NCT02507232 | |
 Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma | II | Recruiting | NCT02847559 | |
 NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma | II | Recruiting | NCT01894061 | |
 Trial of Combination TTF (Optune), Nivolumab Plus/Minus Ipilimumab for Bevacizumab-Naive, Recurrent Glioblastoma | II | Recruiting | NCT03430791 | |
 A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM) | II | Recruiting | NCT02343549 | |
 Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) | III | Completed | NCT00916409 | |
 Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) | III | Completed | NCT00379470 | |
 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI | IV | Recruiting | NCT03297125 | |
 Optune (NOVOTTF-100A), Bevacizumab, & Hypofractionated Stereotactic Irradiation In Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344) | N/A | Recruiting | NCT01925573 | |
 NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme | N/A | Recruiting | NCT01954576 | |
 TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM | N/A | Active, not recruiting | NCT03780569 | |
 Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma | N/A | Active, not recruiting | NCT01892397 | |
 Use of Optune TTF With Radiation as an Alternative for Elderly Patients With Primary CNS Lymphoma | N/A | Not yet recruiting | NCT03530605 | |
 Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma | N/A | Not yet recruiting | NCT03450850 | |
 NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma | N/A | Recruiting | NCT03353896 | |
 Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma | N/A | Recruiting | NCT03033992 | |
GI | ||||
 Study of the NovoTTF-100 L System to Enhance Antitumor Activity in Patients With Predominant Hepatic Metastatic Cancer | I | Not yet recruiting | NCT03203525 | |
 Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA) | I/II | Active, not recruiting | NCT01971281 | |
 Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA) | II | Recruiting | NCT03606590 | |
 Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) | III | Recruiting | NCT03377491 | |
GYN | ||||
 Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE/ENGOT-ov50) | I/II | Recruiting | NCT02244502 | |
 Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Platinum-resistant Ovarian Cancer (PROC) (ENGOT-ov50 / GOG-3029 / INNOVATE-3) | N/A | Recruiting | NCT03940196 | |
LUNG | ||||
 NovoTTF-100 L in Combination With Pemetrexed (Alimta) for Advanced Non-small Cell Lung Cancer | I/II | Completed | NCT00749346 | |
 Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR) | II | Completed | NCT02397928 | |
 Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) | III | Recruiting | NCT02973789 | |
METS | ||||
 Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1–5 Brain Metastases Following Optimal Standard Local Treatment (COMET) | II | Active, not recruiting | NCT01755624 | |
 Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1–10 Brain Metastases Following Radiosurgery (METIS) | III | Recruiting | NCT02831959 | |
 Tumor-Treating Fields Therapy in Preventing Brain Tumors in Participants With Extensive-Stage Small Cell Lung Cancer | N/A | Recruiting | NCT03607682 | |
 Radiosurgery Plus NovoTTF-200A for Metastatic Small Cell Lung Cancer to the Brain (RAD 1704) | N/A | Recruiting | NCT03488472 | |
SKIN | ||||
 Optune Device - TTField Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis | II | Not yet recruiting | NCT03903640 | |